Frazier Lifesciences SPAC said in talks to take NewAmsterdam Pharma public

Jul. 19, 2022 4:30 PM ETNewAmsterdam Pharma Company N.V. (NAMS), NAMSWBy: Joshua Fineman, SA News Editor

Wooden blocks with word SPAC. Special-purpose acquisition company. A easy way stock exchange financial instrument for attracting investments. Development of new simplified procedures for investment

Andrii Yalanskyi

  • SPAC Frazier Lifesciences Acquisition Corp. (NASDAQ:FLAC) is said in talks to take biotech company NewAmsterdam Pharma public.
  • Frazier (FLAC) is in talks to with investors for a PIPE that would value the combined company at more than $700 million, according to a Bloomberg report.
  • NewAmsterdam, a biotech focused on treating metabolic diseases, announced in January 2021 that it completed a a $196 million Series A funding round. Investors in the round included Kaiser Foundation Hospital, Peter Thiel, Janus Henderson Investors and JVC Investment Partners.
  • SPAC Frazier Lifesciences (FLAC) priced a $120 million IPO in December 2020. FLAC said at the time it intended to focus on the biotechnology sector in developed countries including, but not limited to, the United States and countries in Europe.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.